These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22306388)

  • 21. Efficacy and tolerability of switching to ziprasidone in italian patients with acute exacerbation of schizophrenia: an open-label trial.
    Mencacci C;
    Pharmacopsychiatry; 2012 Sep; 45(6):236-40. PubMed ID: 22592506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats.
    Erbas O; Yilmaz M
    Toxicol Ind Health; 2015 Dec; 31(12):1152-7. PubMed ID: 23625911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Electrocardiographic changes in children and adolescents treated with ziprasidone: a prospective study.
    Blair J; Scahill L; State M; Martin A
    J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):73-9. PubMed ID: 15608546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH
    Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
    Goff DC; McEvoy JP; Citrome L; Mech AW; Bustillo JR; Gil R; Buckley P; Manschreck TC; Achtyes ED; Macklin EA
    J Clin Psychopharmacol; 2013 Aug; 33(4):485-90. PubMed ID: 23775057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Scott LJ
    CNS Drugs; 2006; 20(12):1027-52. PubMed ID: 17140281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The safety of atypical antipsychotics: does QTc provide all the answers?
    Nielsen J
    Expert Opin Drug Saf; 2011 May; 10(3):341-4. PubMed ID: 21504386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aripiprazole-associated QTc prolongation in a geriatric patient.
    Hategan A; Bourgeois JA
    J Clin Psychopharmacol; 2014 Dec; 34(6):766-8. PubMed ID: 25203469
    [No Abstract]   [Full Text] [Related]  

  • 29. Ziprasidone security in overdose: one case report.
    Rodriguez Martinez A; Castaño Asins J
    Actas Esp Psiquiatr; 2007; 35(4):282-3. PubMed ID: 17717866
    [No Abstract]   [Full Text] [Related]  

  • 30. No significant QTc interval changes with high-dose ziprasidone: a case series.
    Levy WO; Robichaux-Keene NR; Nunez C
    J Psychiatr Pract; 2004 Jul; 10(4):227-32. PubMed ID: 15552544
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ziprasidone: the fifth atypical antipsychotic.
    Caley CF; Cooper CK
    Ann Pharmacother; 2002 May; 36(5):839-51. PubMed ID: 11978164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerability of ziprasidone: an expanding perspective.
    Daniel DG
    J Clin Psychiatry; 2003; 64 Suppl 19():40-9. PubMed ID: 14728089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Additive effects of ziprasidone and D,L-sotalol on the action potential in rabbit Purkinje fibres and on the hERG potassium current.
    Ducroq J; Printemps R; Le Grand M
    J Pharmacol Toxicol Methods; 2005; 52(1):115-22. PubMed ID: 15922632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Oral Ziprasidone and Oral Haloperidol on QTc interval in patients with Schizophrenia or Schizoaffective disorder.
    Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano R; O'Gorman C; Harrigan RH
    Pharmacotherapy; 2010 Feb; 30(2):127-35. PubMed ID: 20099987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Probable quetiapine-mediated prolongation of the QT interval.
    Aghaienia N; Brahm NC; Lussier KM; Washington NB
    J Pharm Pract; 2011 Oct; 24(5):506-12. PubMed ID: 21844216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin syndrome caused by ziprasidone alone.
    Lin PY; Hong CJ; Tsai SJ
    Psychiatry Clin Neurosci; 2010 Jun; 64(3):338-9. PubMed ID: 20602736
    [No Abstract]   [Full Text] [Related]  

  • 38. Drug-Induced Systemic Hypersensitivity Reaction Associated With Ziprasidone: An Atypical Occurrence.
    Lister JF; Voinov B; Thimothy L; Bean JR
    J Clin Psychopharmacol; 2015 Aug; 35(4):478-80. PubMed ID: 26120944
    [No Abstract]   [Full Text] [Related]  

  • 39. Prospective observational multi-poison center study of ziprasidone exposures.
    Klein-Schwartz W; Lofton AL; Benson BE; Spiller HA; Crouch BI
    Clin Toxicol (Phila); 2007; 45(7):782-6. PubMed ID: 17926152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic Pisa syndrome associated with switching antipsychotics from olanzapine to ziprasidone.
    Yeh YW; Chen YC; Chen CK; Feng HM; Wang TY; Chen CL
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):162-3. PubMed ID: 19028541
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.